Key facts
- Apnimed’s last known valuation is $434.0M (Mar 2026).
- It has raised $434.3M across 8 recorded rounds; the latest was Early Stage VC ($25.0M) in Mar 2026.
- Notable investors include Alpha Wave Global, Morningside Group, Tao Capital Partners, Columbia Seligman, NexPoint (Asset Management) — 7 tracked in total.
- Apnimed has filed 15 Form Ds with the SEC since 2018, most recently Mar 2026 ($25.0M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Apnimed
Funding rounds
8 roundsAbout Apnimed
Developer of a pharmacologic therapy designed to target orally dosed medicines, the key underlying neurobiological mechanisms that lead to airway obstruction. The company's therapeutics address the physiologic and symptomatic effects of obstructive sleep apnea, providing patients with a safe and effective treatment that addresses the underlying biology of the disease.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 78
- Website
- apnimed.com/
- Ownership
- Privately Held (backing)
Apnimed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apnimed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apnimed in its N-PORT filings yet. We sweep new filings monthly.